# Exploration of the influence of GOLGA8B on prostate cancer progression and the resistance of castration-resistant prostate cancer to cabazitaxel

**Authors:** Haopeng Li, Xin’an Wang, Menghe Zhai, Chengdang Xu, Xi Chen

PMC · DOI: 10.1007/s12672-024-00973-7 · Discover Oncology · 2024-05-10

## TL;DR

This study explores how the gene GOLGA8B affects prostate cancer progression and resistance to the drug cabazitaxel in advanced cases.

## Contribution

The study identifies GOLGA8B as a novel gene linked to prostate cancer progression and drug resistance.

## Key findings

- GOLGA8B expression is associated with immune cell infiltration and is upregulated in prostate cancer and CRPC samples.
- GOLGA8B influences sensitivity of CRPC cells to cabazitaxel and docetaxel.
- GOLGA8B affects overall prognosis and disease-free survival in prostate cancer patients.

## Abstract

Castration-resistant prostate cancer (CRPC) represents the final stage of prostate cancer (PCa). Cabazitaxel, a taxane chemotherapy drug, is used in treating CRPC. However, patients with CRPC eventually develop resistance to cabazitaxel, and the underlying mechanism remains unclear. Here, we aimed to investigate potential genetic alterations that may play a role in CRPC resistance to cabazitaxel. Using microarray data from the GSE158494 dataset, we identified ten critical genes (CXCL8, ITGB8, CLIP4, MAP1B, WIPI1, MMP13, CXCL1, C1S, GOLGA8B, and CXCL6) associated with CRPC cell resistance to cabazitaxel. The potential function of these key genes in PCa progression was analyzed using different databases, including Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), and Chinese Prostate Cancer Genome and Epigenome Atlas (CPGEA). Our findings revealed altered expression of these genes in the development of PCa. Furthermore, CXCL1 and GOLGA8B were found to influence the disease-free survival (DFS) status of patients with PCa, with GOLGA8B affecting the overall prognosis in patients with PCa. Additionally, GOLGA8B expression was associated with the infiltration of various immune cells in PCa, and it was upregulated in clinical PCa and CRPC samples. Through CCK-8 assays, we established that GOLGA8B could influence the sensitivity of CRPC cells to cabazitaxel and docetaxel. In conclusion, we identified GOLGA8B as a crucial gene that influences PCa progression and contributes to CRPC resistance to cabazitaxel.

The online version contains supplementary material available at 10.1007/s12672-024-00973-7.

## Linked entities

- **Genes:** GOLGA8B (golgin A8 family member B) [NCBI Gene 440270], CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919], CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576], ITGB8 (integrin subunit beta 8) [NCBI Gene 3696], CLIP4 (CAP-Gly domain containing linker protein family member 4) [NCBI Gene 79745], MAP1B (microtubule associated protein 1B) [NCBI Gene 4131], WIPI1 (WD repeat domain, phosphoinositide interacting 1) [NCBI Gene 55062], MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322], C1S (complement C1s) [NCBI Gene 716], CXCL6 (C-X-C motif chemokine ligand 6) [NCBI Gene 6372]
- **Chemicals:** cabazitaxel (PubChem CID 9854073), docetaxel (PubChem CID 148124)
- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** GOLGA8B (golgin A8 family member B) [NCBI Gene 440270] {aka GOLGA5}, CLIP4 (CAP-Gly domain containing linker protein family member 4) [NCBI Gene 79745] {aka RSNL2}, MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, WIPI1 (WD repeat domain, phosphoinositide interacting 1) [NCBI Gene 55062] {aka ATG18, ATG18A, WIPI49}, ITGB8 (integrin subunit beta 8) [NCBI Gene 3696], CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, MAP1B (microtubule associated protein 1B) [NCBI Gene 4131] {aka DFNA83, FUTSCH, MAP5, PPP1R102, PVNH9}, CXCL6 (C-X-C motif chemokine ligand 6) [NCBI Gene 6372] {aka CKA-3, GCP-2, GCP2, SCYB6}, C1S (complement C1s) [NCBI Gene 716] {aka EDSPD2}
- **Diseases:** Cancer (MESH:D009369), PCa (MESH:D011471), CRPC (MESH:D064129)
- **Chemicals:** taxane (MESH:C080625), Cabazitaxel (MESH:C552428), docetaxel (MESH:D000077143)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11087400/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11087400/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC11087400/full.md

---
Source: https://tomesphere.com/paper/PMC11087400